الرابطة الدولية لمكافحة المواد الطبيّة المزورة a WHO initiative to combat counterfeit medical products Dr V. Reggi - World Health Organization.

Slides:



Advertisements
Similar presentations
BSEC Working Group on Institutional Renewal and Good Governance March 26-27, 2007 Istanbul The Black Sea NGOs Network.
Advertisements

The Admissibility of Electronic Evidence at Court: fighting against high tech crime AGIS 2005 Fredesvinda Insa, PhD Strategic Development Manager CYBEX.
4 th Global Congress Combating Counterfeiting & Piracy Dubai, February 3-8, 2008 Challenge 7 : Strengthening Cooperation and Collaboration at the Global.
1 n European Commission 4th Global Congress: Combating Counterfeiting and Piracy Dubai – 3 February 2008 An Urgent Need to Better Respond to the Global.
INTERPOL General Secretariat 2008 Building Anti-Counterfeiting Capacity and Capabilities David Asante-Apeatu Director Specialized Crime and Analysis INTERPOL.
Thematic Discussion on Human Rights & Resolution 1373 Counter-Terrorism Committee Executive Directorate (CTED) United Nations New York, 7 October 2010.
Child Protection Units
1 EU/UNICEF project to end torture and ill-treatment against children.
Inter-American Security Observatory: Crime and Violence(OIS) Department of Public Security Secretariat for Multidimensional Security General Secretariat.
Copyright of the Health Sciences Authority 2007 ASEAN-China Conference on Combating Counterfeit Medical Products Jakarta, November 2007 Singapore.
IMPACT Principles and Elements for National Legislation Presented by: Chair, Working Group on Regulatory Implementation, on behalf of Chair, Working Group.
International Medical Products Anti-CounterfeitingTaskforce INSPECTOR OF DRUGS NATIONAL DRUG AUTHORITY- UGANDA.
International Medical Products Anti-CounterfeitingTaskforce.
Anti- Piracy Unit (APU) REPUBLIC OF MAURITIUS 1. MAURITIUS 2.
International Medical Products Anti-CounterfeitingTaskforce.
IMPACT REGIONAL CONFERENCE ON COMBATING COUNTERFEIT MEDICAL PRODUCT: 9-10 NOVEMBER 2009: KEMPTON PARK,SOUTH AFRICA: BY DETECTIVE INSPECTOR NAMIBIA.
IMPACT Regional Conference on Combacting Counterfeit Medical Products 9-10 November 2009 Kempton Park – South Africa Mozambique Experience.
International Medical Products Anti-CounterfeitingTaskforce.
WHO Good Distribution Practices for Pharmaceutical Products
First ASEAN-China Conference on Combating Counterfeit Medical Products Jakarta November 2007 CHOO CHEOK HANG DEPARTMENT OF PHARMACEUTICAL SERVICES.
A WHO initiative to combat counterfeit medical products Dr V. Reggi World Health Organization.
International Telecommunication Union An Insight into BDT Programme 3 Marco Obiso ICT Applications and Cybersecurity Division Telecommunication Development.
1 n European Commission Third Global Congress on Combating Counterfeiting and Piracy Geneva – 30 and 31 January 2007 The European Union: Coordination and.
Ministry of Interior of Montenegro,,The Fight against corruption and organized crime in Montenegro Ministry of Interior of Montenegro,,The Fight against.
Importance of community-based services for persons with disabilities: Availability and quality International frame June 2012,Belgrade Dr.Vasilka.
DG Enterprise and Industry Approach on Combating Counterfeit Medicines Council of Europe Conference “Europe against Counterfeit Medicines” Session: Key.
Promoting patient-centred healthcare around the world Counterfeit Medicines: The views and role of patients and patients’ organizations Jeremiah Mwangi.
World Health Organization
Panel themes of the International Conference “Europe against Counterfeit Medicines” G.N. Gildeeva, Deputy head of the Department of Registration of Medicines.
Counterfeit Medicines and Fight against Counterfeit Medicines.
Brand Protection: In the face of mounting counterfeiting, diversion & other infringements Jim Mentone | Director, Consumer Global Brand Protection.
PSM India Bejon Misra, Founder Director.
Strengthening the Protection of Intellectual and Industrial Property Rights Deputy Manager Jan Hylleberg The Danish Association of the Pharmaceutical Industry.
MeTa, Solwezi 27 August,2013.  A branded- name drug product is originally discovered and developed by a pharmaceutical company.  Branded-name drugs.
Complete ACTA negotiations and implement in 2010 Expand counterfeiting and piracy database Enhance transparency and monitoring Build respect for IPR’s.
2011 Overall Objectives Contributing toward limiting Violence against Women, and fostering the role of the NCHR in combating VAW focusing on domestic.
Counter-Terrorism Implementation Task Force (CTITF) Open Briefing to Member States 27 July 2010 Conference Room 2 NLB.
THE ROLE OF CIVIL SOCIETY IN WELFARE MIX MODEL CREATION Best Practice Model Social Center "Home of colors"
Regulations Relating to Foodstuffs for Infants and Young Children (Foodstuffs, Cosmetics and Disinfectants Act, 1972) Briefing to the Portfolio Committee.
> In April of 2007, Main Pharmaceutical Inspector created special position for combating counterfeit and illegal medicines > In May,
The emergence of an Enforcement Agenda Intellectual Property Rights and Access to Essential Medicines: Challenges and Opportunities in Free Trade Agreement.
Programming of International Development Assistance Donor Sectoral Meeting Ministry of Interior September 17, 2007.
ALL-UKRAINIAN PUBLIC ORGANIZATION “PUBLIC TRANSPORT SAFETY COMMITTEE”
Medicines Transparency Alliance01/10/2015 Availability of Medicines Anita Wagner Harvard Medical School & WHO Collaborating Center in Pharmaceutical Policy.
Strengthening the Protection and Enforcement of Intellectual Property Rights in Ukraine Activity October 2014.
Margarit MELIKYAN Drug Utilization Research Group PO, Armenia, National Institute of Health Access to and Use of Medicines by Households in Armenia: Impact.
1 OIE Response to the HPAI Threat in the SADC Region 1 st SADC Meeting on Avian Influenza Pretoria, South Africa 7-9 March 2006 Sub Regional Representation.
MALAWI GOVERNMENT MINISTRY OF HEALTH PROGRESS ON GOOD GOVERNANCE IN THE PHARMACEUTICAL SECTOR IN MALAWI By Dr Charles Mwansambo Secretary for Health 20.
A project implemented by the HTSPE consortium This project is funded by the European Union SECURITY AND CITIZENSHIP PERICLES
THE PRIORITIES OF PUBLIC ADMINISTRATION REFORM IN THE MIDDLE EAST THE PRIORITIES OF PUBLIC ADMINISTRATION REFORM IN THE MIDDLE EAST 1. Decentralization.
RER/9/096 Regional Planning Meeting “Strengthening National Infrastructures for the Control of Radiation Sources” (TSA-1), (Phase II) Country: Republic.
International cooperation in combating IP crimes: Criminal IP enforcement in the international policy debate Heike Wollgast World Intellectual Property.
Enforcement under the TRIPS Agreement [Shortened version of presentation] Regional Conference – IP Enforcement Cairo, November 9, 2008 Ms. Louise van Greunen.
Prevention of Corruption by the Directorate for Anti-Corruption Initiative Bratislava, 30 June – 1 July
National Information Communication Technologies Strategy Vasif Khalafov “National strategy” working group - Web -
Quality & Safety of Generic Drugs in the World Market World Bank Conference “Good Intentions – Bad Drugs” March 10, 2005 Washington, D.C. Christine Simmon.
INTRODUCTION AND OBJECTIVES LEGAL ASPECTS AND SOCIO-ECONOMIC IMPLICATIONS REGARDING DRUG COUNTERFEITING CIOBANU CONSTANTIN, CORCIOVĂ ANDREIA Faculty of.
National Public Health Performance Standards Local Assessment Instrument Essential Service:6 Enforce Laws and Regulations that Protect Health and Ensure.
IMPACT - Regional Meeting on Combating Counterfeit Medical Products 9-10 November 2009, Kempton Park South Africa WHO Survey on situation of counterfeit.
ADDRESSING PHARMACEUTICAL SUPPLY CHAIN NEEDS PRESENTATION TO HEALTH DONOR GROUP MEETING 8 July 2009.
Prepared by: Imon Rahman Lecturer Department of Pharmacy BRAC University.
MeTA Phase I: Where are we? MeTA18/06/ MeTA2 The MeTA Phase I Proposal Purpose To pilot a new multi-stakeholder approach towards increasing transparency.
1 IMPACT: the International Medical Products Anti-Counterfeiting Taskforce Peter Munyi LLM Christa Cepuch BSc Phm UNSR EAC Consultation, Nairobi 10 – 12.
ACCESS TO QUALITY MEDICINES IN THE REGION-COUNTERFEITING PROBLEMS
Establishing the Infrastructure for Radiation Safety Preparatory Actions and Initial Regulatory Activities.
a WHO initiative to combat counterfeit medicines
Fight Against Falsified medicines
Counterfeiting and Intellectual property theft in Medicines World Bank Symposium March 10, 2005 Washington DC Frederick Razzaghi Director of Technical.
National Medicines Policies
An Enabling Business Environment and A Strategy and Collaborative Approach for Sustainable Quality Local Production Africa Pharma Conference 4-5 June 2019,
Presentation transcript:

الرابطة الدولية لمكافحة المواد الطبيّة المزورة a WHO initiative to combat counterfeit medical products Dr V. Reggi - World Health Organization

الرابطة الدولية لمكافحة المواد الطبيّة المزورة WHO definition a medicine, which is deliberately and fraudulently mislabelled with respect to identity and/or source. Counterfeiting can apply to both branded and generic products and counterfeit products may include products with the correct ingredients, with the wrong ingredients, without active ingredients, with the incorrect amount of active ingredients or with fake packaging

الرابطة الدولية لمكافحة المواد الطبيّة المزورة A counterfeit medical product is …. ……not a medical product! Arbitrary and unpredictable composition Manufactured evading regulatory control Manufactured and sold hiding its real origin Meant to deceive, unsafe

الرابطة الدولية لمكافحة المواد الطبيّة المزورة It is not primarily an IP issue! It is mainly a personal and public health problem! Medical products are not bags, CDs, watches or T-shirts! A counterfeit medical product …. 2005: 3 women killed in Argentina by a counterfeit iron preparation 2006: 300+ people killed in Panama by mislabelled glycerine

الرابطة الدولية لمكافحة المواد الطبيّة المزورة … jeopardizes the credibility of health care delivery systems, pharmaceutical supply systems, … and governments! A counterfeit medical product ….

الرابطة الدولية لمكافحة المواد الطبيّة المزورة IMPACT is a taskforce launched by WHO to gather all the most important international actors in the fight against the counterfeiting of medical products IMPACT aims at coordinating global action in order to promote and protect public health. What is IMPACT ?

الرابطة الدولية لمكافحة المواد الطبيّة المزورة IMPACT approach: collaboration among all those concerned is essential OTHER PUBLIC SECTOR INSTITUTIONS MANUFACTURERS DISTRIBUTION SYSTEM PATIENTS PERIPHERAL PUBLIC SECTOR INSTITUTIONS BORDER CONTROL AUTHORITIES POLICE & OTHER ENFORCEMENT AUTHORITIES HEALTH PROFESSIONALS DRUG REGULATORY AUTHORITIES JUDICIARY MEDIA FAKE MEDICAL PRODUCTS

الرابطة الدولية لمكافحة المواد الطبيّة المزورة IMPACT AFTER 1 YEAR Secretariat: WHO 5 working groups: legislative and regulatory infrastructure regulatory implementation enforcement technology communication

الرابطة الدولية لمكافحة المواد الطبيّة المزورة LEGISLATIVE & REGULATORY INFRASTRUCTURE

الرابطة الدولية لمكافحة المواد الطبيّة المزورة ENFORCEMENT Coordination of operations among participating countries Internet monitoring and purchases Training materials and manuals to improve skills of enforcement officers Improve information exchange

الرابطة الدولية لمكافحة المواد الطبيّة المزورة INTERPOL and WHO are strengthening their collaboration to support countries to combat counterfeit medical products

الرابطة الدولية لمكافحة المواد الطبيّة المزورة ENFORCEMENT ASEAN+China Conference - November 2007, Jakarta 10 ASEAN Member Countries + China Drug regulatory authorities, police, customs, associations of health professionals, manufacturers, wholesalers, NGOs. Result: - launched the establishment of a SPOC-based network; - preparatory work for new coordinated operation (in the wake of Jupiter South-East Asia operation that lead to identifying source of counterfeit antimalarials)

الرابطة الدولية لمكافحة المواد الطبيّة المزورة IMPACT toolkit Experience from different countries; Model legislation & regulations; Training materials and methodologies; Tools and manuals to assist national authorities in implementing activities; Tools and methodologies for the assessment of national/regional situations.

الرابطة الدولية لمكافحة المواد الطبيّة المزورة What can countries do? Strengthen legislation ensuring a) counterfeiting medical products is a crime and b) punishment is commensurate to the consequences that it has on personal health and on the credibility of national health systems. Strengthen regulatory oversight (including in so-called free zones) ensuring that all manufacturers, importers, exporters, distributors and retailers comply with the appropriate requirements that are necessary for a secure distribution chain. Improve collaboration among governmental entities (such as health, police, customs, local administrative units, judiciary), private sector and civil society in order to effectively combat counterfeiters. Develop a communication strategy to ensure that health professionals, the general public and the media are aware of the dangers associated with counterfeit medicines.

الرابطة الدولية لمكافحة المواد الطبيّة المزورة Thank you